Patient, disease, and transplant-related characteristics
| Variables . | HLA-identical sibling transplant . | Autologous transplant . | P . |
|---|---|---|---|
| N | 76 | 128 | |
| Age, y, median (range) | 27 (5-53) | 31 (2-67) | .01 |
| Men or boys (%) | 53 (70) | 91 (71) | .84 |
| Karnofsky performance score at transplantation (%) | .53 | ||
| 80% or lower | 47 (62) | 82 (64) | |
| 90%-100% | 27 (36) | 39 (30) | |
| Unknown | 2 (2) | 7 (6) | |
| Disease status at transplantation (%) | .86 | ||
| CR1 | 24 (32) | 47 (37) | |
| Second or subsequent CR | 16 (20) | 23 (18) | |
| Relapse | 18 (24) | 31 (24) | |
| Primary induction failure | 18 (24) | 27 (21) | |
| Bone marrow involvement at transplantation (%) | .09 | ||
| Absent | 51 (67) | 92 (72) | |
| Present | 10 (13) | 6 (5) | |
| Unknown | 15 (20) | 30 (23) | |
| CNS involvement at transplantation (%) | .20 | ||
| Absent | 61 (80) | 105 (83) | |
| Present | 12 (16) | 12 (9) | |
| Unknown | 3 (4) | 11 (8) | |
| Serum LDH at diagnosis (%) | .18 | ||
| Less than 1.5 upper normal limit | 63 (83) | 94 (74) | |
| 1.5 × upper normal limit or higher | 13 (17) | 31 (24) | |
| Unknown | — | 3 (2) | |
| Initial chemotherapy (%) | .55 | ||
| Adriamycin containing regimen | 42 (61) | 60 (47) | |
| Others, not adriamycin | 11 (16) | 13 (10) | |
| Others, not specified | 16 (23) | 55 (43) | |
| Chemosensitivity at transplantation | .09 | ||
| Sensitive | 57 (75) | 88 (69) | |
| Resistant | 11 (14) | 12 (9) | |
| Untreated/unknown | 8 (11) | 28 (22) | |
| Graft type | < .001 | ||
| Bone marrow | 56 (74) | 54 (42) | |
| Peripheral blood | 20 (26) | 61 (48) | |
| Both | — | 13 (10) | |
| Year of transplant | .04 | ||
| 1989-1993 | 12 (16) | 36 (28) | |
| 1994-1998 | 64 (84) | 92 (72) | |
| Use of TBI | 51 (67) | 50 (39) | < .001 |
| G-CSF given within 7 d after transplantation | .43 | ||
| No | 36 (47) | 68 (53) | |
| Yes | 40 (53) | 60 (47) | |
| Acute GVHD (%) | — | ||
| Grades 0-I | 53 (70) | — | |
| Grade II | 10 (13) | — | |
| Grade III | 9 (12) | — | |
| Grade IV | 4 (5) | — | |
| Chronic GVHD (%) | 13 (17)* | ||
| Median follow-up of survivors, mo (range) | 32 (3-122) | 44 (3-124) |
| Variables . | HLA-identical sibling transplant . | Autologous transplant . | P . |
|---|---|---|---|
| N | 76 | 128 | |
| Age, y, median (range) | 27 (5-53) | 31 (2-67) | .01 |
| Men or boys (%) | 53 (70) | 91 (71) | .84 |
| Karnofsky performance score at transplantation (%) | .53 | ||
| 80% or lower | 47 (62) | 82 (64) | |
| 90%-100% | 27 (36) | 39 (30) | |
| Unknown | 2 (2) | 7 (6) | |
| Disease status at transplantation (%) | .86 | ||
| CR1 | 24 (32) | 47 (37) | |
| Second or subsequent CR | 16 (20) | 23 (18) | |
| Relapse | 18 (24) | 31 (24) | |
| Primary induction failure | 18 (24) | 27 (21) | |
| Bone marrow involvement at transplantation (%) | .09 | ||
| Absent | 51 (67) | 92 (72) | |
| Present | 10 (13) | 6 (5) | |
| Unknown | 15 (20) | 30 (23) | |
| CNS involvement at transplantation (%) | .20 | ||
| Absent | 61 (80) | 105 (83) | |
| Present | 12 (16) | 12 (9) | |
| Unknown | 3 (4) | 11 (8) | |
| Serum LDH at diagnosis (%) | .18 | ||
| Less than 1.5 upper normal limit | 63 (83) | 94 (74) | |
| 1.5 × upper normal limit or higher | 13 (17) | 31 (24) | |
| Unknown | — | 3 (2) | |
| Initial chemotherapy (%) | .55 | ||
| Adriamycin containing regimen | 42 (61) | 60 (47) | |
| Others, not adriamycin | 11 (16) | 13 (10) | |
| Others, not specified | 16 (23) | 55 (43) | |
| Chemosensitivity at transplantation | .09 | ||
| Sensitive | 57 (75) | 88 (69) | |
| Resistant | 11 (14) | 12 (9) | |
| Untreated/unknown | 8 (11) | 28 (22) | |
| Graft type | < .001 | ||
| Bone marrow | 56 (74) | 54 (42) | |
| Peripheral blood | 20 (26) | 61 (48) | |
| Both | — | 13 (10) | |
| Year of transplant | .04 | ||
| 1989-1993 | 12 (16) | 36 (28) | |
| 1994-1998 | 64 (84) | 92 (72) | |
| Use of TBI | 51 (67) | 50 (39) | < .001 |
| G-CSF given within 7 d after transplantation | .43 | ||
| No | 36 (47) | 68 (53) | |
| Yes | 40 (53) | 60 (47) | |
| Acute GVHD (%) | — | ||
| Grades 0-I | 53 (70) | — | |
| Grade II | 10 (13) | — | |
| Grade III | 9 (12) | — | |
| Grade IV | 4 (5) | — | |
| Chronic GVHD (%) | 13 (17)* | ||
| Median follow-up of survivors, mo (range) | 32 (3-122) | 44 (3-124) |
CR indicates complete remission; CNS, central nervous system; LDH, lactate dehydrogenase; TBI, total body irradiation; GVHD, graft-versus-host disease; and —, not applicable.
A total of 75 patients were evaluable.